The Neprilysin Pathway in Heart Failure: A Review and Guide on the Use of Sacubitril/Valsartan

Heart - United Kingdom
doi 10.1136/heartjnl-2014-306775
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Perceived Barriers to Sacubitril/Valsartan Use in Patients With Heart Failure

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2018English

Sacubitril-Valsartan in Heart Failure and Multimorbidity Patients

ESC heart failure
Cardiovascular MedicineCardiology
2018English

Reply: Sacubitril/Valsartan for Chagas' Heart Disease Heart Failure?

ESC heart failure
Cardiovascular MedicineCardiology
2018English

Cost-Effectiveness of Sacubitril/Valsartan in the Treatment of Heart Failure in Colombia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Sacubitril/Valsartan Use for the Hospitalist

American Journal of Hospital Medicine
2017English

Pcv6 - Sacubitril/Valsartan in Heart Failure: Projected Health Outcomes in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Profile of Sacubitril/Valsartan in the Treatment of Heart Failure: Patient Selection and Perspectives

Vascular Health and Risk Management
2017English

The Combination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure - An Update

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2017English

The Reverse Remodeling Response to Sacubitril/Valsartan Therapy in Heart Failure With Reduced Ejection Fraction

Cardiovascular Therapeutics
MedicineCardiovascular MedicinePharmacologyCardiology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy